-

Eurofins Environment Testing Adds Omicron Variant Detection to its SARS-CoV-2 Monitoring Solution for Wastewater, Surface, Air and Worn Masks

LUXEMBOURG--(BUSINESS WIRE)--Eurofins Environment Testing adds Omicron variant detection capabilities to its commercially available SARS-CoV-2 test portfolio. The Omicron variant has been identified as a ‘variant of concern’ by the World Health Organization (WHO) due to the high number of mutations in the spike protein and indications of high transmissibility.

The monitoring of wastewater, environmental surface, air and worn mask testing, available as part of the Eurofins COVID-19 Sentinel™ and SAFER@WORK™ programs, provides an early warning of the presence of SARS-CoV-2 and its variants amongst large populations or at a given site. This provides crucial information for monitoring viral spread and allows for relevant containment measures to be put in place to avoid an outbreak of the disease even before symptom onset.

Eurofins Environment Testing is able to detect all known SARS-CoV-2 variants in wastewater, air, environmental surfaces and worn masks. Utilizing single point mutations in RT-qPCR, the currently dominant Delta variant can be distinguished from other variants including the new Omicron variant.

For more information, visit EurofinsUS.com/Env.

About Eurofins Environment Testing America
The Eurofins Environment Testing network in the US contributes to a clean and safe environment by providing market-leading laboratory testing, monitoring, and consulting services to a wide range of industrial companies, environmental consultants, contractors, retailers and government authorities.

About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With 55,000 staff across a network of 900 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.

Eurofins Shares are listed on Euronext Paris Stock Exchange.

Contacts

Brian Williams
ir@eurofins.com

Eurofins Scientific

BOURSE:ERF

Release Versions

Contacts

Brian Williams
ir@eurofins.com

More News From Eurofins Scientific

Eurofins Scientific SE: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at 31 January 2026

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (Paris:ERF): ANNEXE B Form to be used for the disclosure of the total number of voting rights and capital, in accordance with the law and grand-ducal regulation of 11 January 2008 on transparency requirements for issuers of securities 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedi (including the issuer ID allocated by the CSSF) EUROFINS SCIENTIFIC SE – E1013 2. Identi...

Eurofins Scientific SE: Weekly Report on Share Repurchases from 02nd February to 06th February 2026

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (Paris:ERF): Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 02/02/2026 FR0014000MR3 10 000 68.3375 XPAR EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 03/02/2026 FR0014000MR3 10 000 67.9091 XPAR EUROFINS SCIENTIFIC 529900JEHFM...

Eurofins Viracor BioPharma Expands Bioanalytical Capabilities

LUXEMBOURG--(BUSINESS WIRE)--Eurofins Viracor BioPharma Services, a long‑standing and trusted partner for clinical trial testing solutions with deep expertise in specialty biomarkers and molecular assays, announces a significant expansion of its service portfolio with the addition of enhanced bioanalytical testing capabilities. These new services are fully aligned with Good Laboratory Practices (GLP) and Good Clinical Practices (GCP), enabling the company to enhance support of biopharmaceutical...
Back to Newsroom